Cardio Diagnostics (CDIO) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anbio Biotechnology is the larger company by market cap ($215.1 million vs $5.8 million), about 37.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | NNNN |
|---|---|---|
| Share price | $1.96 | $4.90 |
| Market cap | $5.80M | $215.07M |
| 1-day change | -2.00% | 0.00% |
| YTD return | — | -83.70% |
| 1-year return | — | -83.37% |
| P/E ratio (TTM) | — | 32.67 |
| EPS (TTM) | $-2.87 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $44.73 |
| 52-week low | $0.97 | $4.66 |
| Distance from 52-week high | -75.22% | -89.05% |
| Average volume | 55.78K | 148.96K |
| Shares outstanding | 2.96M | 43.89M |
| Employees | — | 27 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 37.1 times larger than Cardio Diagnostics by market value ($215.07M vs $5.80M).
- The two companies sit in different sectors: Cardio Diagnostics in Health Care and Anbio Biotechnology in Healthcare.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Healthcare · Medical Instruments & Supplies · 27 employees
CDIO vs NNNN FAQ
Which is bigger, Cardio Diagnostics or Anbio Biotechnology?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $215.07M compared with $5.80M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Anbio Biotechnology in the same industry?
No. Cardio Diagnostics is in the Health Care sector, while Anbio Biotechnology is in Healthcare.